Pulmonary 2-deoxy-2-[18F]-fluoro-d-glucose uptake is low in treated patients with idiopathic pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 3, 2013, Pages 647-653

  Ruiter, Gerrina ^a   Wong, Yeun Ying ^a   Raijmakers, Pieter ^b   Huisman, Marc C ^b   Lammertsma, Adriaan A ^b   Knaapen, Paul ^a   de Man, Frances S ^a   Westerhof, Nico ^a   van Der Laarse, Willem J ^a   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glucose analogue; Glycolysis; Nuclear medicine; Positron emission tomography; Pulmonary hypertension

Indexed keywords

EID: 84919684954     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674335     Document Type: Article

References (16)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14): 1425-1436.
2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-1263.
3. 18Ffluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185(6):670-679.
4. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 2012;185(3):260-266.
5. 18F]-2-fluoro-2-deoxy-Dglucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27(6): 731-743.
6. Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104(4):1342-1347.
7. 18FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: a proof-of-principle study. Pulm Circ 2011;1(4):448-455.
8. Wong YY, Ruiter G, Lubberink M, et al. Right ventricular failure in idiopathic pulmonary arterial hypertension is as-sociated with inefficient myocardial oxygen utilization. Circ Heart Fail 2011;4(6):700-706.
9. Bax JJ, Veening MA, Visser FC, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging: a comparative study using different protocols. Eur J Nucl Med 1997;24(1):35-41.
10. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009;54 (16):1524-1532.
11. van Campen CM, Visser FC, van der Weerdt AP, et al. FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging 2007;34(3):309-315.
12. 18F-FDG: standardized uptake values in normal tissues. J Nucl Med 2004;45(5):784-788.
13. Patlak CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5(4):584-590.
14. Michelakis ED, McMurtry MS, Wu XC, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002;105(2):244-250.
15. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987;60(11):2682-2689.
16. Brudin LH, Valind SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994;21(4):297-305